Journal Article

2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis

Tsukamoto, Tatsuo, Mukhtyar, Chetan, Tesar, Vladimir, Kamali, Sevil, Suzuki, Kazuo, Sharma, Aman, Jayne, David, Grainger, Rebecca, Chakravarty, Kuntal, Mclaren, John, Tak, Paul-Peter, Rodrigues, Miguel, Diamantopoulos, Andreas, Pirila, Laura, Sznajd, Jan, Gewurz-Singer, Ora, Shahin, Amira, Moreno, Xavier Solanich, Liang, Kimberly, Yamagata, Kunihiro, Mason, Justin, Berglin, Ewa, Khalid, Sara, Robson, Joanna, Schiavon, Franco, Amano, Koichi, Matteson, Eric, Luqmani, Raashid A, Maw, Win Win, Azevedo, Elsa, Moiseev, Sergey, Merkel, Peter A., Das, Siddharth, Patel, Sanjeev, Dobashi, Hiroaki, Kono, Hajime, Wada, Takashi, Sreih, Antoine, Calabrese, Leonard, Henes, Jörg, Sunderkoetter, Cord, Honma, Sakae, Yumura, Wako, Harigai, Masayoshi, Uchida, Shunya, Ikeda, Kei, Morgan, Ann, Santos, Ernestina, Daikeler, Thomas, Menon, Ajit, Tombetti, Enrico, Direskeneli, Haner, Quincey, Vicki, Neumann, Thomas, Pehlevan, Seval, Hassan, Alaa, Carette, Simon, Clarkson, Michael, Danda, Debashish, Albert, Daniel, Lamprecht, Peter, Baslund, Bo, Klocke, Rainer, Fujimoto, Shouichi, Song, Yeong-Wook, Hirahashi, Junichi, Luqmani, Raashid, Makino,

2022

Overview

ObjectiveTo develop and validate revised classification criteria for eosinophilic granulomatosis with polyangiitis (EGPA).MethodsPatients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in five phases: (1) identification of candidate criteria items using consensus methodology, (2) prospective collection of candidate items present at the time of diagnosis, (3) data-driven reduction of the number of candidate items, (4) expert panel review of cases to define the reference diagnosis and (5) derivation of a points-based risk score for disease classification in a development set using least absolute shrinkage and selection operator logistic regression, with subsequent validation of performance characteristics in an independent set of cases and comparators.ResultsThe development set for EGPA consisted of 107 cases of EGPA and 450 comparators. The validation set consisted of an additional 119 cases of EGPA and 437 comparators. From 91 candidate items, regression analysis identified 11 items for EPGA, 7 of which were retained. The final criteria and their weights were as follows: maximum eosinophil count ≥1×109/L (+5), obstructive airway disease (+3), nasal polyps (+3), cytoplasmic antineutrophil cytoplasmic antibody (ANCA) or anti-proteinase 3–ANCA positivity (−3), extravascular eosinophilic predominant inflammation (+2), mononeuritis multiplex/motor neuropathy not due to radiculopathy (+1) and haematuria (−1). After excluding mimics of vasculitis, a patient with a diagnosis of small- or medium-vessel vasculitis could be classified as having EGPA if the cumulative score was ≥6 points. When these criteria were tested in the validation data set, the sensitivity was 85% (95% CI 77% to 91%) and the specificity was 99% (95% CI 98% to 100%).ConclusionThe 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis demonstrate strong performance characteristics and are validated for use in research.

• Publisher: BMJ Publishing Group Ltd and European League Against Rheumatism,Elsevier Limited
• Subject: Adult / Allergic diseases / Antibodies / Antibodies, Antineutrophil Cytoplasmic - blood / Antineutrophil cytoplasmic antibodies / Arthritis / autoimmune diseases / Classification / Creatinine / Criteria / Datasets / Diagnosis / Diagnosis, Differential / Disease / Eosinophilic Granuloma - classification / Eosinophilic Granuloma - diagnosis / Europe / Female / Granulomatosis / Granulomatosis with Polyangiitis - classification / Granulomatosis with Polyangiitis - diagnosis / Hearing loss / Hematuria / Humans / Inflammatory diseases / Leukocytes (eosinophilic) / Male / Middle Aged / Myeloblastin - immunology / Neuropathy / Polyps / Prospective Studies / Proteinase 3 / rehabilitation / Reproducibility of Results / Respiratory tract diseases / Rheumatology / Rheumatology - standards / Risk Factors / Sensitivity and Specificity / Societies / United States / Vasculitis / Vein & artery diseases / Websites